Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today